Method, device and system for controlling flow rate of medicine, monitoring equipment and medium

Abstract

The invention relates to the technical field of childbirth monitoring, and discloses a method, device and system for controlling the flow rate of medicine, monitoring equipment and a medium, and the method for controlling the flow rate of the medicine comprises the steps that uterine electromyographic signals of a monitored pregnant woman are obtained; characteristic parameters and / or uterine contraction parameters are / is determined according to the uterine electromyographic signals, the characteristic parameters and the uterine contraction parameters are used for representing the uterine activity degree of the monitored pregnant woman, and the characteristic parameters at least comprise one or more of a time domain parameter, a frequency domain parameter and a nonlinear parameter; the uterine contraction parameters at least comprise one or more of uterine contraction intensity, uterine contraction times, uterine contraction frequency, uterine contraction duration and uterine contraction interval duration; controlling the infusion pump to adjust the flow rate of the medicine according to the characteristic parameters and / or the uterine contraction parameters. The dosage can be accurately controlled based on the uterus electromyographic signals, medical workers are assisted in completing work, and the production safety of pregnant women is improved.

Description

Technical Field

[0001] The present invention relates to the technical field of childbirth monitoring, and particularly relates to a method, device, system, monitoring device and medium for controlling the drug flow rate. Background Art

[0002] Uterine contractions (labor contractions) can prompt the fetus to be expelled from the mother's body. Regular labor contractions are an important feature of labor onset, and labor contraction monitoring is of great significance for ensuring the health of the mother and fetus. The method of collecting uterine myoelectric signals through surface electrode patches placed on the abdominal wall of the parturient and then detecting labor contractions based on the uterine myoelectric signals has received extensive attention due to its advantages such as non-invasiveness and being less affected by external factors such as obesity.

[0003] Currently, medical staff can evaluate the labor contractions of a pregnant woman based on the uterine myoelectric signals and then adjust the drug flow rate in the infusion pump accordingly to control the drug dosage. However, evaluating the labor contractions of a pregnant woman based on the uterine myoelectric signals depends on the medical staff's understanding of the uterine myoelectric signals, which has a certain degree of subjectivity and there is a problem of being unable to accurately control the drug dosage. Summary of the Invention

[0004] In view of this, the present invention provides a method, device, system, monitoring device and medium for controlling the drug flow rate to solve the problem of being unable to accurately control the drug dosage.

[0005] In a first aspect, the present invention provides a method for controlling the drug flow rate, the method comprising: obtaining the uterine myoelectric signals of a monitored pregnant woman; determining characteristic parameters and / or labor contraction parameters according to the uterine myoelectric signals, wherein the characteristic parameters and the labor contraction parameters are both used to characterize the uterine activity degree of the monitored pregnant woman, the characteristic parameters at least include one or more of time domain parameters, frequency domain parameters and non-linear parameters, and the labor contraction parameters at least include one or more of labor contraction intensity, labor contraction times, labor contraction frequency, labor contraction duration and labor contraction interval duration; controlling an infusion pump to adjust the drug flow rate according to the characteristic parameters and / or the labor contraction parameters.

[0006] The method for controlling the drug flow provided in this embodiment, after acquiring the myoelectrical signals of the uterus of the monitored pregnant woman, determines the characteristic parameters and / or contraction parameters characterizing the activity degree of the uterus according to the myoelectrical signals of the uterus, and then controls an infusion pump to adjust the flow rate of the drug based on the characteristic parameters and / or contraction parameters. The present invention characterizes the activity degree of the uterus of the monitored pregnant woman through time domain parameters, frequency domain parameters, non-linear parameters and / or contraction parameters, can provide a more comprehensive basis for quantitative analysis, improve the accuracy of characterizing the activity degree of the uterus, and thus can more accurately control the dosage of the drug, avoiding problems such as the failure to achieve the due effect due to too little dosage or damage to the maternal and fetal nervous systems caused by too much dosage. Moreover, automatically controlling the dosage of the drug for the monitored pregnant woman according to the characteristic parameters and / or contraction parameters can assist medical staff to complete their work, ensure the real-time nature of the monitoring, and improve the safety of pregnant women during childbirth. In addition, the quantified time domain parameters, frequency domain parameters and non-linear parameters can be used as a measurement basis to assist medical staff in subsequent treatment.

[0007] In an optional implementation manner, the controlling the infusion pump to adjust the flow rate of the drug according to the characteristic parameters and / or the contraction parameters includes: inputting the characteristic parameters into a trained machine learning model; controlling the infusion pump to adjust the flow rate of the drug according to the contraction parameters and / or the indication information output by the machine learning model.

[0008] The method for controlling the drug flow provided in this embodiment, after determining the characteristic parameters and / or contraction parameters characterizing the activity degree of the uterus according to the acquired myoelectrical signals of the uterus, inputs the characteristic parameters into a pre-trained machine learning model, and then controls the infusion pump to adjust the flow rate of the drug according to the contraction parameters and / or the indication information output by the pre-trained machine learning model. The present invention can more efficiently and accurately control the dosage of the drug through the machine learning model. In this embodiment, determining the activity degree of the uterus of the monitored pregnant woman through the contraction parameters and the indication information can improve the accuracy of the determined activity degree of the uterus.

[0009] In an optional implementation manner, the method further includes: acquiring the individual characteristic information of the monitored pregnant woman, where the individual characteristic information includes at least one of name, age, gestational week, clinical symptoms and drug type; the controlling the infusion pump to adjust the flow rate of the drug according to the contraction parameters and / or the indication information output by the machine learning model includes: controlling the infusion pump to adjust the flow rate of the drug according to the individual characteristic information and the target parameters, where the target parameters are the indication information output by the machine learning model and / or the contraction parameters.

[0010] In an alternative embodiment, controlling the infusion pump to adjust the flow rate of the drug according to the individual characteristic information and the target parameter includes: determining the status of the monitored pregnant woman according to the individual characteristic information, where the status is a fetal protection status or an induction of labor status; when the monitored pregnant woman is in the fetal protection status, controlling the infusion pump to adjust the flow rate of the drug according to a first control strategy, where the indication information includes the first control strategy; when the monitored pregnant woman is in the induction of labor status, controlling the infusion pump to adjust the flow rate of the drug according to a second control strategy, where the indication information includes the second control strategy.

[0011] In an alternative embodiment, when the monitored pregnant woman is in the fetal protection status, controlling the infusion pump to adjust the flow rate of the drug according to a first control strategy includes: when the monitored pregnant woman is in the fetal protection status, if the uterine activity level of the monitored pregnant woman is greater than or equal to a first preset uterine activity level, then according to the first control strategy, controlling the infusion pump to increase the flow rate of the drug, where the uterine activity level is determined based on the target parameter; when the monitored pregnant woman is in the fetal protection status, if the uterine activity level of the monitored pregnant woman is less than the first preset uterine activity level, then according to the first control strategy, controlling the infusion pump to keep the flow rate of the drug unchanged.

[0012] In an alternative embodiment, when the monitored pregnant woman is in the induction of labor status, controlling the infusion pump to adjust the flow rate of the drug according to a second control strategy includes: when the monitored pregnant woman is in the induction of labor status, if the uterine activity level of the monitored pregnant woman is greater than or equal to a second preset uterine activity level, then according to the second control strategy, controlling the infusion pump to decrease the flow rate of the drug, where the uterine activity level is determined based on the target parameter; when the monitored pregnant woman is in the induction of labor status, if the uterine activity level of the monitored pregnant woman is less than the second preset uterine activity level, then according to the second control strategy, controlling the infusion pump to increase the flow rate of the drug.

[0013] In an alternative embodiment, the method further includes: during the process of controlling the infusion pump to increase the flow rate of the drug, if the flow rate of the drug reaches the maximum flow rate, controlling the infusion pump to stop increasing the flow rate of the drug.

[0014] In an alternative embodiment, determining the characteristic parameter and / or the uterine contraction parameter according to the myometrial electrical signal includes: preprocessing the myometrial electrical signal to obtain a processed myometrial electrical signal, where the preprocessing includes at least one of filtering out interference signals and rectification processing; determining the characteristic parameter and / or the uterine contraction parameter according to the processed myometrial electrical signal.

[0015] In this embodiment, after obtaining the myometrial electrical signal, preprocessing the myometrial electrical signal and determining the characteristic parameter and / or the uterine contraction parameter according to the preprocessed myometrial electrical signal can more accurately and efficiently determine the characteristic parameter and / or the uterine contraction parameter.

[0016] In an alternative embodiment, the method further includes: displaying at least one of the myometrial electrical signal, the characteristic parameter, the uterine contraction parameter, the drug flow rate in the infusion pump, the drug type in the infusion pump, and the remaining amount of the drug in the infusion pump through a display.

[0017] In this embodiment, displaying information such as the myometrial electrical signal, the characteristic parameter, the uterine contraction parameter, the flow rate of the drug in the infusion pump, the type of the drug in the infusion pump, and the remaining amount of the drug in the infusion pump on the display can facilitate medical staff to observe and understand the status of the monitored pregnant woman.

[0018] In a second aspect, the present invention provides a device for controlling the drug flow rate, including: an acquisition module for acquiring the myometrial electrical signal of a monitored pregnant woman; a processing module for determining a characteristic parameter and / or a uterine contraction parameter according to the myometrial electrical signal, where the characteristic parameter and the uterine contraction parameter are both used to characterize the uterine activity degree of the monitored pregnant woman, the characteristic parameter includes at least one or more of a time domain parameter, a frequency domain parameter, and a non-linear parameter, and the uterine contraction parameter includes at least one or more of uterine contraction intensity, uterine contraction frequency, uterine contraction duration, and uterine contraction interval duration; a control module for controlling the infusion pump to adjust the drug flow rate according to the characteristic parameter and / or the uterine contraction parameter.

[0019] In an alternative embodiment, the control module includes: an input unit for inputting the characteristic parameter into a trained machine learning model; a first control unit for controlling the infusion pump to adjust the drug flow rate according to the uterine contraction parameter and / or the indication information output by the machine learning model.

[0020] In an alternative embodiment, the device includes: a first acquisition unit configured to acquire individual characteristic information of a pregnant woman under monitoring, where the individual characteristic information includes at least one of name, age, gestational week, clinical symptom, and drug type; the first control unit includes: a first control subunit configured to control an infusion pump to adjust the flow rate of a drug according to the individual characteristic information and a target parameter, where the target parameter is an indication information and / or a contraction parameter.

[0021] In an alternative embodiment, the first control subunit includes: a first determination unit configured to determine the status of the pregnant woman under monitoring according to the individual characteristic information, where the status is a fetal protection status or an induction of labor status; a first adjustment unit configured to, when the pregnant woman under monitoring is in the fetal protection status, control the infusion pump to adjust the flow rate of the drug according to a first control strategy, where the indication information includes the first control strategy; a second adjustment unit configured to, when the pregnant woman under monitoring is in the induction of labor status, control the infusion pump to adjust the flow rate of the drug according to a second control strategy, where the indication information includes the second control strategy.

[0022] In an alternative embodiment, the first adjustment unit includes: a first adjustment subunit configured to, when the pregnant woman under monitoring is in the fetal protection status, if the uterine activity level of the pregnant woman under monitoring is greater than or equal to a first preset uterine activity level, control the infusion pump to increase the flow rate of the drug according to the first control strategy, where the uterine activity level is determined based on the target parameter; a second adjustment subunit configured to, when the pregnant woman under monitoring is in the fetal protection status, if the uterine activity level of the pregnant woman under monitoring is less than the first preset uterine activity level, control the infusion pump to keep the flow rate of the drug unchanged according to the first control strategy.

[0023] In an alternative embodiment, the second adjustment unit includes: a third adjustment subunit configured to, when the pregnant woman under monitoring is in the induction of labor status, if the uterine activity level of the pregnant woman under monitoring is greater than or equal to a second preset uterine activity level, control the infusion pump to decrease the flow rate of the drug according to the second control strategy, where the uterine activity level is determined based on the target parameter; a fourth adjustment subunit configured to, when the pregnant woman under monitoring is in the induction of labor status, if the uterine activity level of the pregnant woman under monitoring is less than the second preset uterine activity level, control the infusion pump to increase the flow rate of the drug according to the second control strategy.

[0024] In an alternative embodiment, the device further comprises: a stop module, configured to control the infusion pump to stop increasing the flow rate of the drug when the flow rate of the drug reaches the maximum flow rate during the process of increasing the flow rate of the drug in the infusion pump.

[0025] In an alternative embodiment, the processing module comprises: a first processing unit, configured to preprocess the uterine electromyogram signal to obtain a processed uterine electromyogram signal, wherein the preprocessing comprises at least one of filtering out interference signals and rectification processing; a second processing unit, configured to determine the characteristic parameter and / or the uterine contraction parameter according to the processed uterine electromyogram signal.

[0026] In an alternative embodiment, the control module comprises: a fourth control unit, configured to display at least one of the uterine electromyogram signal, the characteristic parameter, the uterine contraction parameter, the flow rate of the drug in the infusion pump, the type of the drug in the infusion pump, and the remaining amount of the drug in the infusion pump through a display.

[0027] In a third aspect, the present invention provides a system for controlling the flow rate of a drug, comprising a uterine electromyogram signal acquisition device, a processor, and an infusion pump; the uterine electromyogram signal acquisition device is configured to acquire the uterine electromyogram signal of a monitored pregnant woman; the processor is configured to obtain the uterine electromyogram signal from the uterine electromyogram signal acquisition device, determine a characteristic parameter and / or a uterine contraction parameter according to the uterine electromyogram signal, and control the infusion pump to adjust the flow rate of the drug according to the characteristic parameter and / or the uterine contraction parameter, wherein the characteristic parameter and the uterine contraction parameter are both used to characterize the activity degree of the uterus of the monitored pregnant woman, the characteristic parameter at least comprises one or more of a time domain parameter, a frequency domain parameter, and a non-linear parameter, and the uterine contraction parameter at least comprises one or more of uterine contraction intensity, uterine contraction times, uterine contraction frequency, uterine contraction duration, and uterine contraction interval duration.

[0028] In an alternative embodiment, the system further comprises a display; the processor is further configured to display at least one of the uterine electromyogram signal, the characteristic parameter, the uterine contraction parameter, the flow rate of the drug in the infusion pump, the type of the drug in the infusion pump, and the remaining amount of the drug in the infusion pump through the display.

[0029] In a fourth aspect, the present invention provides a monitoring device, comprising: a memory and a processor, which are communicatively connected to each other, wherein the memory stores computer instructions, and the processor executes the computer instructions to execute the method according to the first aspect or any corresponding embodiment thereof.

[0030] Fifth aspect, the present invention provides a computer-readable storage medium, on which computer instructions are stored, and the computer instructions are used to cause a computer to execute the method according to the first aspect or any corresponding embodiment thereof as described above. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] In order to more clearly illustrate the specific embodiments of the present invention or the technical solutions in the related art, the following will briefly introduce the drawings required to be used in the description of the specific embodiments or the related art. Obviously, the drawings in the following description are some embodiments of the present invention. For those of ordinary skill in the art, without creative efforts, other drawings can also be obtained based on these drawings.

[0032] Figure 1 is a flowchart of a method for controlling the drug flow rate according to an embodiment of the present invention;

[0033] Figure 2 is a schematic diagram of a monitoring interface according to an embodiment of the present invention;

[0034] Figure 3 is a flowchart of another method for controlling the drug flow rate according to an embodiment of the present invention;

[0035] Figure 4 is a flowchart of yet another method for controlling the drug flow rate according to an embodiment of the present invention;

[0036] Figure 5 is a structural block diagram of a device for controlling the drug flow rate according to an embodiment of the present invention;

[0037] Figure 6 is a structural block diagram of a system for controlling the drug flow rate according to an embodiment of the present invention;

[0038] Figure 7 is a schematic diagram of the hardware structure of a monitoring device according to an embodiment of the present invention. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0039] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the following will clearly and completely describe the technical solutions in the embodiments of the present invention with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are some, but not all, of the embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts fall within the scope of protection of the present invention.

[0040] At present, the methods for detecting uterine contraction (UC) adopted clinically are mainly divided into manual palpation, internal monitoring and external monitoring. Among them, manual palpation is carried out by experienced doctors who feel uterine contractions by palpating the pregnant woman's abdomen. It is greatly affected by subjective factors, which is not conducive to quantifying uterine contractions and is not convenient for long-term monitoring. Internal monitoring mainly uses an intrauterine pressure gauge. An intrauterine pressure catheter (IUPC) equipped with a pressure sensor is placed on the presenting part of the fetus to measure the pressure data in the uterine cavity (such as amniotic fluid pressure), and then the uterine contraction situation is determined based on the pressure data. Internal monitoring can accurately measure the pressure data in the uterine cavity and is regarded as the gold standard for uterine contraction detection. However, this method requires the rupture of the membrane to place the detection catheter, which increases the risk of intrauterine infection and may cause complications such as uterine perforation, fetal bleeding injury and even placental abruption.

[0041] External monitoring includes tocodynamometer (TOCO) and the method based on electrohystrography (EHG) of the uterine body surface. External monitoring is non-invasive and is the most widely used measurement method in current clinical practice. When using TOCO for monitoring, a belt is wrapped around the parturient's abdomen, and uterine contractions are felt by measuring strain. The pressure measured in this way is affected by the initial measurement pressure and the tightness of the belt binding, and is not applicable to some pregnant women such as those who are obese. For the method based on EHG, the electrohysterogram signal of the uterus is directly detected by surface electrode patches placed on the abdominal wall of the parturient, and uterine contraction monitoring is carried out by evaluating the electrohysterogram signal. Specifically, the electrohysterogram signal is the electrical activity of the pregnant uterus detected from the surface of the pregnant woman's body, which is the comprehensive manifestation of the individual electrical activities of countless uterine smooth muscle cells. Uterine contraction is the result of the propagation of action potentials along uterine muscle cells in the form of intermittent burst waves. The intensity of uterine contraction is related to the degree of propagation of action potentials and the number of recruited muscle cells. As childbirth approaches, the excitability and connectivity of uterine muscle layer cells increase, resulting in an increase in the propagation of action potentials, an increase in the intensity and synchrony of electrohysterogram signals, which often corresponds to perceptible uterine contractions.

[0042] Compared with TOCO, this non-invasive method for monitoring uterine contractions based on electrohysterogram signals of the uterine body surface has higher consistency with the intrauterine pressure measured by IUPC by extracting the envelope information of electrohysterogram signals, and has the advantages of not being easily affected by obesity and the tightness of the binding belt, etc., and can safely and stably obtain the state of uterine activity.

[0043] Since existing uterine electromyogram devices mainly reflect the generation time and intensity of uterine electromyogram burst waves corresponding to uterine contractions to indicate the occurrence of uterine contractions, medical staff need to subjectively judge the uterine contraction situation based on their understanding of uterine electromyogram-related knowledge and then control the dosage of drugs. However, at present, due to the lack of popularization of the clinical application of uterine electromyogram signals, medical staff do not understand the information contained in uterine electromyogram signals, resulting in the problem of inaccurate drug dosage control.

[0044] In view of this, the present invention provides a method for controlling drug flow, which can accurately control the drug dosage based on uterine electromyogram signals, assist medical staff in completing their work, and improve the safety of pregnant women during childbirth.

[0045] According to an embodiment of the present invention, an embodiment of a method for controlling drug flow is provided. It should be noted that the steps shown in the flowchart of the accompanying drawings can be executed in a monitoring device such as a set of computer-executable instructions. And although the logical order is shown in the flowchart, in some cases, the steps shown or described can be executed in a different order than here.

[0046] In this embodiment, a method for controlling drug flow is provided, which can be used for the above-mentioned monitoring device. Figure 1 It is a flowchart of a method for controlling drug flow according to an embodiment of the present invention, as Figure 1 shown, the method includes the following steps:

[0047] Step S101, acquiring the uterine electromyogram signal of the monitored pregnant woman.

[0048] Specifically, the surface electrode patches are attached to the abdomen of the monitored pregnant woman to collect the bioelectric signals of the abdominal wall of the monitored pregnant woman, and then the uterine electromyogram signal of the monitored pregnant woman is acquired. That is, the uterine electromyogram signal is the bioelectric signal generated by the uterus during activity recorded by the surface electrode patches attached to the abdomen of the monitored pregnant woman. The non-invasive surface electrode patches are closely attached to the skin, ensuring that the uterine electromyogram signal of the pregnant woman's abdominal wall can be obtained safely and stably during the monitoring process.

[0049] Step S102, determining characteristic parameters and / or uterine contraction parameters according to the uterine electromyogram signal.

[0050] Among them, the characteristic parameters and uterine contraction parameters are used to characterize the activity degree of the uterus of the monitored pregnant woman. The characteristic parameters include at least one of time domain parameters, frequency domain parameters, and non-linear parameters. The uterine contraction parameters include at least one or more of uterine contraction intensity, uterine contraction frequency, uterine contraction duration, and uterine contraction interval duration.

[0051] Specifically, the time domain and the frequency domain are the basic characteristics of a signal. The time domain parameters are the characteristics of the uterine electromyogram signal in the time domain, such as amplitude or peak value, etc. The frequency domain parameters are the characteristics of the uterine electromyogram signal in the frequency domain, such as peak frequency, median frequency, and average power frequency, etc. The time domain parameters and the frequency domain parameters can be converted into each other through Fourier series or Fourier transform. Nonlinear features can be understood as features that do not satisfy the addition principle, such as approximate entropy and sample entropy, etc.

[0052] Exemplarily, the characteristic parameters may only include time domain parameters or frequency domain parameters or nonlinear parameters, or may include time domain parameters, frequency domain parameters, and nonlinear parameters. Based on the time domain parameters, frequency domain parameters, and nonlinear parameters together to determine the flow rate of the drug in the infusion pump can accurately control the flow rate of the drug in the infusion pump.

[0053] Specifically, after obtaining the uterine electromyogram signal, as Figure 2 shown, the amplitude envelope signal of the uterine electromyogram signal can be extracted. The reference horizontal line of the envelope curve is determined according to the envelope signal, and then the start and end points (start point and end point) of each uterine contraction (uterine contraction) are determined according to the intersection points of the envelope signal and the reference horizontal line. The maximum value of the envelope signal between the start and end points of each uterine contraction is the peak value of the uterine contraction. Then, the uterine contraction frequency is determined according to the number of uterine contractions within the acquisition period, the uterine contraction intensity is determined according to the peak values of the uterine contractions within the acquisition period, the duration of the uterine contraction is determined according to the start and end points of the uterine contraction, and the interval duration between two adjacent uterine contractions is determined according to the start points of the two adjacent uterine contractions. Among them, the acquisition period is a preset value. For example, the acquisition period can be 20 minutes (min), 30 min, or 60 min, etc.

[0054] For example, if the acquisition period is 20 min and the number of uterine contractions within the acquisition period is 4, the uterine contraction frequency can be 2 times / 10 min. If the peak value of the first uterine contraction is 72, the peak value of the second uterine contraction is 74, the peak value of the third uterine contraction is 71, and the peak value of the fourth uterine contraction is 73, then the uterine contraction intensity = (72 + 74 + 71 + 75) ÷ 4 = 73, that is, the uterine contraction intensity is the average value of the peak values of the uterine contractions within the acquisition period.

[0055] Step S103, control the infusion pump to adjust the flow rate of the drug according to the characteristic parameters and / or the uterine contraction parameters.

[0056] Among them, the drug can be a uterine contraction inhibitor, an oxytocic, or an anesthetic, etc.

[0057] Specifically, the flow rate of the drug in the infusion pump can be adjusted by controlling the rotation speed of the infusion pump.

[0058] Exemplarily, after determining the characteristic parameter and / or the uterine contraction parameter, the degree of uterine activity can be determined. For example, when any one of the characteristic parameter and / or the uterine contraction parameter is less than the first preset value, it indicates that the degree of uterine activity is low (i.e., the degree of uterine activity is less than the preset degree of uterine activity). When any one of the characteristic parameter and / or the uterine contraction parameter is greater than or equal to the first preset value and less than or equal to the second preset value, it indicates that the degree of uterine activity is normal. When any one of the characteristic parameter and / or the uterine contraction parameter is greater than the second preset value, it indicates that the degree of uterine activity is high (i.e., the degree of uterine activity is greater than the preset degree of uterine activity). Then, according to the degree of uterine activity and the corresponding relationship, the target flow rate of the drug in the infusion pump is determined, and further, the flow rate of the drug in the infusion pump is adjusted to the target flow rate by controlling the rotation speed of the infusion pump.

[0059] Among them, the target flow rate can be fixed or variable. When determining the target flow rate, a fixed flow rate or a variable flow rate can be selected according to the actual needs based on the comparison relationship.

[0060] For example, the corresponding relationship can be as shown in Table 1.

[0061] Table 1

[0062]

[0063] Exemplarily, when it is determined that the degree of uterine activity is high, according to Table 1, the target flow rate of the drug in the infusion pump can be determined to be 60 mL / h, or the current flow rate can be reduced at a rate of 1 mL / h. The current flow rate is the flow rate of the drug in the infusion pump at the current moment.

[0064] The method for controlling the drug flow provided in this embodiment, after acquiring the myoelectrical signal of the uterus of the monitored pregnant woman, determines the characteristic parameter and / or the uterine contraction parameter characterizing the degree of uterine activity according to the myoelectrical signal of the uterus, and then controls the infusion pump to adjust the flow rate of the drug based on the characteristic parameter and / or the uterine contraction parameter. The present invention characterizes the degree of uterine activity of the monitored pregnant woman through time domain parameters, frequency domain parameters, non-linear parameters, and / or uterine contraction parameters, can provide a more comprehensive quantitative analysis basis, improve the accuracy of characterizing the degree of uterine activity, and further can control the drug dosage more accurately, avoiding problems such as insufficient drug dosage not achieving the desired effect or excessive drug dosage causing damage to the maternal and fetal nervous systems. Moreover, automatically controlling the drug dosage of the monitored pregnant woman according to the characteristic parameter and / or the uterine contraction parameter can assist medical staff to complete their work, ensure the real-time nature of monitoring, and improve the safety of pregnant women during childbirth. In addition, the quantified time domain parameters, frequency domain parameters, and non-linear parameters can be used as a measurement basis to assist medical staff in subsequent treatment.

[0065] The following further describes step S103 in the method for controlling the drug flow provided by the present invention with reference to the accompanying drawings.

[0066] In this embodiment, a method for controlling the drug flow rate is provided, which can be used in the above-mentioned monitoring device. Figure 3 It is a schematic flowchart of another method for controlling the drug flow rate according to an embodiment of the present invention. As Figure 3 shown, the method includes the following steps:

[0067] Step S301, obtain the myoelectrical signal of the uterus of the pregnant woman under monitoring.

[0068] For details, please refer to Figure 1 step S101 of the embodiment shown, which will not be elaborated here.

[0069] Step S302, determine the characteristic parameter and / or the contraction parameter according to the myoelectrical signal of the uterus.

[0070] For details, please refer to Figure 1 step S102 of the embodiment shown, which will not be elaborated here.

[0071] Step S303, control the infusion pump to adjust the flow rate of the drug according to the characteristic parameter and / or the contraction parameter.

[0072] Specifically, the above step S303 includes:

[0073] Step S3031, input the characteristic parameter into the trained machine learning model.

[0074] Exemplarily, the machine learning model can be a support vector machine or a neural network model, etc.

[0075] Specifically, multiple myoelectrical signals of the uterus can be collected in advance, and the myoelectrical signals of the uterus are labeled to form a sample database. Then, based on the sample database, with the myoelectrical signal of the uterus as the input and the indication information as the output, the machine learning model is trained until the output error of the machine learning model is less than the preset value, and the trained machine learning model is obtained.

[0076] Step S3032, control the infusion pump to adjust the flow rate of the drug according to the contraction parameter and / or the indication information output by the machine learning model.

[0077] Exemplarily, when determining the characteristic parameter according to the myoelectrical signal of the uterus, input the characteristic parameter into the trained machine learning model, and then control the flow rate of the drug of the infusion pump according to the indication information output by the machine learning model. At this time, the indication information can be information indicating an increase in the flow rate, information indicating a decrease in the flow rate, or information indicating that the flow rate remains unchanged. For example, if the current flow rate of the drug in the infusion pump is 20 mL / h, and both the increase and decrease amplitudes are 5 mL / h, then when the indication information output by the machine learning model is an increase in the flow rate, control the infusion pump to adjust the flow rate to 25 mL / h; when the indication information output by the machine learning model is a decrease in the flow rate, control the infusion pump to adjust the flow rate to 15 mL / h.

[0078] When determining the uterine contraction parameters based on the myoelectrical signals of the uterus, the uterine activity level of the monitored pregnant woman is determined according to the uterine contraction parameters, and then the infusion pump is controlled according to the uterine activity level to adjust the flow rate of the drug. When any one of the uterine contraction parameters is greater than or equal to the corresponding preset uterine contraction parameter, it indicates a high uterine activity level. When any one of the uterine contraction parameters is less than the corresponding preset uterine contraction parameter, it indicates a low uterine activity level. After determining the uterine activity level, the infusion pump is controlled according to the uterine activity level and the corresponding relationship to adjust the flow rate of the drug.

[0079] For example, the corresponding relationship can be as shown in Table 2 or Table 3.

[0080] Table 2

[0081] Degree of uterine activity Low High Flow rate 20 mL / h 40 mL / h

[0082] Specifically, when the monitored pregnant woman is in the fetal protection mode, when it is determined that the uterine activity level is high, the flow rate can be gradually and slowly increased to 40 mL / h according to Table 2. When it is determined that the uterine activity level is low, the flow rate can be gradually and slowly decreased to 20 mL / h according to Table 2.

[0083] Table 3

[0084] Degree of uterine activity Low High Flow rate 20 mL / h 15 mL / h

[0085] Specifically, when the monitored pregnant woman is in the induction of labor mode, when it is determined that the uterine activity level is low, the flow rate can also be gradually and slowly increased to 20 mL / h according to Table 3. When it is determined that the uterine activity level is high, the flow rate can be gradually and slowly decreased to 15 mL / h according to Table 3.

[0086] When determining the characteristic parameters and uterine contraction parameters based on the myoelectrical signals of the uterus, the characteristic parameters are input into the trained machine learning model, and then the uterine activity level of the monitored pregnant woman is determined according to the uterine contraction parameters and the indication information output by the machine learning model. Then, the flow rate of the drug of the infusion pump is controlled according to the uterine activity level. At this time, the indication information can be the information indicating the uterine activity level of the monitored pregnant woman. When the indication information indicates a high uterine activity level and any one of the uterine contraction parameters is greater than or equal to the corresponding preset uterine contraction parameter, it indicates a high uterine activity level. When the indication information indicates a low uterine activity level and any one of the uterine contraction parameters is less than the corresponding preset uterine contraction parameter, it indicates a low uterine activity level.

[0087] The method for controlling the drug flow provided in this embodiment, after determining the characteristic parameters and / or contraction parameters representing the uterine activity degree according to the obtained myoelectrical signals of the uterus, inputs the characteristic parameters into a pre-trained machine learning model, and then controls an infusion pump to adjust the drug flow rate according to the contraction parameters and / or the indication information output by the pre-trained machine learning model. Through the machine learning model, the present invention can control the drug dosage more efficiently and accurately. In this embodiment, by determining the uterine activity degree of the monitored pregnant woman through the contraction parameters and the indication information, the accuracy of the determined uterine activity degree can be improved.

[0088] In this embodiment, a method for controlling the drug flow is provided, which can be used for the above-mentioned monitoring device. Figure 4 It is a schematic flowchart of another method for controlling the drug flow according to an embodiment of the present invention, as Figure 4 shown, the method includes the following steps:

[0089] Step S401, obtain the myoelectrical signals of the uterus of the monitored pregnant woman.

[0090] For details, please refer to Figure 1 Step S101 of the embodiment shown, which will not be elaborated here.

[0091] Step S402, determine the characteristic parameters and / or contraction parameters according to the myoelectrical signals of the uterus.

[0092] Specifically, the above step S402 includes:

[0093] Step S4021, preprocess the myoelectrical signals of the uterus to obtain the preprocessed myoelectrical signals of the uterus.

[0094] Among them, the preprocessing includes at least one of filtering out interference signals and rectification processing.

[0095] Exemplarily, after obtaining the myoelectrical signals of the uterus of the monitored pregnant woman, interference signals such as baseline drift, power frequency interference, maternal electrocardiogram, fetal electrocardiogram, and maternal abdominal skeletal muscle myoelectrical signals can be filtered out through a band-pass filter and a smoothing filter, and / or the myoelectrical signals of the uterus can be rectified to obtain pure myoelectrical signals of the uterus.

[0096] Step S4022, determine the characteristic parameters and / or contraction parameters according to the preprocessed myoelectrical signals of the uterus.

[0097] Specifically, determining the characteristic parameters and / or contraction parameters according to the preprocessed myoelectrical signals of the uterus can reduce interference and improve the accuracy and efficiency of determining the characteristic parameters and / or contraction parameters.

[0098] Step S403, obtain the individual characteristic information of the monitored pregnant woman.

[0099] Among them, the individual characteristic information includes at least one of name, age, gestational week, clinical symptoms, and drug type. Exemplarily, the clinical symptoms may be characteristics such as whether the pregnant woman is bleeding, whether the pregnant woman's amniotic fluid has broken, and whether the pregnant woman has uterine diseases (such as uterine fibroids), and the drug type may be a tocolytic, an oxytocic, an anesthetic, etc.

[0100] Exemplarily, medical staff can input the individual characteristic information into a device for controlling the drug flow rate (such as an electronic device such as a computer or a PC), so that the device for controlling the drug flow rate obtains the individual characteristic information.

[0101] Step S404: Input the characteristic parameters into the trained machine learning model.

[0102] For details, please refer to Figure 3 Step S3031 of the illustrated embodiment, which will not be elaborated here.

[0103] Step S405: Control the infusion pump to adjust the drug flow rate according to the individual characteristic information and the target parameters.

[0104] Among them, the target parameters are the indication information output by the machine learning model and / or the uterine contraction parameters.

[0105] Specifically, the above step S405 includes:

[0106] Step S4051: Determine the status of the monitored pregnant woman according to the individual characteristic information.

[0107] Among them, the status is the fetal protection status or the induction of labor status.

[0108] Specifically, when the monitored pregnant woman is in different states, the medication conditions are different. The status of the monitored pregnant woman can be determined by the gestational week, clinical symptoms, and medication conditions (drug type). When it is determined according to the individual characteristic information that the status of the pregnant woman is in the fetal protection status, the drug type is a tocolytic, and when the gestational week of the monitored pregnant woman is less than 37 weeks, when it is determined according to the individual characteristic information that the status of the pregnant woman is in the induction of labor status, the drug type is an oxytocic, and the gestational week of the monitored pregnant woman is greater than or equal to 37 weeks.

[0109] Step S4052: When the monitored pregnant woman is in the fetal protection status, control the infusion pump to adjust the drug flow rate according to the first control strategy.

[0110] Step S4053: When the monitored pregnant woman is in the induction of labor status, control the infusion pump to adjust the drug flow rate according to the second control strategy.

[0111] Exemplarily, when the monitored pregnant woman is in a state of fetal protection, if the uterine activity level of the monitored pregnant woman is greater than or equal to the first preset uterine activity level, then according to the first control strategy, control the infusion pump to increase the flow rate of the drug. At this time, the first control strategy is to increase the flow rate of the drug in the infusion pump according to the first preset gradient; when the monitored pregnant woman is in a state of fetal protection, if the uterine activity level of the monitored pregnant woman is less than the first preset uterine activity level, then according to the first control strategy, control the infusion pump to keep the flow rate of the drug unchanged. At this time, the first control strategy is to keep the flow rate of the drug in the infusion pump unchanged.

[0112] Specifically, according to the first control strategy, controlling the infusion pump to increase the flow rate of the drug can be to increase the flow rate of the drug in the infusion pump from the current flow rate to the sum of the current flow rate and the first preset gradient. The first preset gradient is the gradient of the flow rate increase set in advance. For example, the first preset gradient is 3 mL / h and the current flow rate is 25 mL / h, then the adjusted flow rate is 28 mL / h.

[0113] Exemplarily, when the monitored pregnant woman is in a state of induction of labor, if the uterine activity level of the monitored pregnant woman is greater than or equal to the second preset uterine activity level, then according to the second control strategy, control the infusion pump to decrease the flow rate of the drug. At this time, the second control strategy is to decrease the flow rate of the drug in the infusion pump according to the second preset gradient; when the monitored pregnant woman is in a state of induction of labor, if the uterine activity level of the monitored pregnant woman is less than the second preset uterine activity level, then according to the second control strategy, control the infusion pump to increase the flow rate of the drug. At this time, the second control strategy is to increase the flow rate of the drug in the infusion pump according to the third preset gradient.

[0114] Specifically, according to the second control strategy, controlling the infusion pump to decrease the flow rate of the drug can be to decrease the flow rate of the drug in the infusion pump from the current flow rate to the difference between the current flow rate and the second preset gradient. The second preset gradient is the gradient of the flow rate decrease set in advance. For example, the second preset gradient is 2 mL / h and the current flow rate is 25 mL / h, then the adjusted flow rate is 23 mL / h. According to the second control strategy, controlling the infusion pump to increase the flow rate of the drug can be to increase the flow rate of the drug in the infusion pump from the current flow rate to the difference between the current flow rate and the third preset gradient. The third preset gradient is the gradient of the flow rate increase set in advance. For example, the third preset gradient is 4 mL / h and the current flow rate is 25 mL / h, then the adjusted flow rate is 29 mL / h.

[0115] Among them, the first preset gradient, the second preset gradient, and the third preset gradient can be the same or different.

[0116] Specifically, the indication information includes a first control strategy and a second control strategy, and the first control strategy and the second control strategy can be pre-configured in the monitoring device by the staff. The first preset uterine activity level and the second preset uterine activity level can be the same or different.

[0117] The uterine activity level is determined by the target parameter. Exemplarily, when the target parameter only includes the uterine contraction parameter, when any parameter in the uterine contraction parameter is greater than or equal to the corresponding preset uterine contraction parameter, it indicates that the uterine activity level is high (that is, the uterine activity level is greater than or equal to the first preset uterine activity level or the second preset uterine activity level). When any parameter in the uterine contraction parameter is less than the corresponding preset uterine contraction parameter, it indicates that the uterine activity level is low (that is, the uterine activity level is less than the first preset uterine activity level or the second preset uterine activity level). When the target parameter only includes the indication information, the indication information can be information indicating the uterine activity level. The present application does not limit the indication information. For example, when the indication information is the character "high", it indicates that the uterine activity level is high. When the indication information is the character "medium", it indicates that the uterine activity level is normal. When the indication information is the character "low", it indicates that the uterine activity level is low. In the case where the target parameter is the uterine contraction parameter and the indication information, when the indication information indicates that the uterine activity level is high, and when any parameter in the uterine contraction parameter is greater than or equal to the corresponding preset uterine contraction parameter, it indicates that the uterine activity level is high. When the indication information indicates that the uterine activity level is low, and when any parameter in the uterine contraction parameter is less than the corresponding preset uterine contraction parameter, it indicates that the uterine activity level is low.

[0118] Specifically, when the pregnant woman is in a fetal protection state, if the uterine activity level is high, it indicates that the monitored pregnant woman has a risk of premature birth. If the uterine activity level is low, it indicates that the monitored pregnant woman has no risk of premature birth.

[0119] It should be noted that during the process of controlling the drug flow rate in the infusion pump to increase, if the drug flow rate reaches the maximum flow rate, the infusion pump is controlled to stop increasing the drug flow rate. That is to say, when the drug flow rate in the infusion pump has reached the set maximum flow rate, the flow rate increase is stopped.

[0120] Exemplarily, when the monitored pregnant woman is in a state of maintaining pregnancy, if the determined uterine activity level is too high, the infusion pump can be controlled to slowly increase the dripping flow rate of the tocolytic agent at a first preset speed (for example, 1 mL / h); if the determined uterine activity level is normal, the input of the tocolytic agent can be stopped or the dripping speed of the tocolytic agent can be stopped from increasing. When the monitored pregnant woman is in a state of induction of labor, if the determined uterine activity level is too low, the infusion pump can be controlled to slowly increase the dripping flow rate of the oxytocic agent at a second preset speed (for example, 1 mL / h or 1.5 mL / h); if the determined uterine activity level is too high, the infusion pump can be controlled to slowly decrease the dripping flow rate of the oxytocic agent at a third preset speed (for example, 0.5 mL / h or 1.5 mL / h), or stop the input of the oxytocic agent.

[0121] Step S406, display at least one of the myometrial electrical signal, characteristic parameters, uterine contraction parameters, flow rate of the drug in the infusion pump, type of the drug in the infusion pump, and remaining amount of the drug in the infusion pump through the display.

[0122] Specifically, during the process of adjusting the flow rate, information such as the myometrial electrical signal, characteristic parameters, uterine contraction parameters, drug flow rate in the infusion pump, drug type in the infusion pump, and remaining amount of the drug in the infusion pump can be displayed on the display, facilitating medical staff to observe and understand the state of the monitored pregnant woman.

[0123] Exemplarily, after obtaining the myometrial electrical signal, the myometrial electrical signal can be traced on the real-time recorded myometrial electrical signal curve. The myometrial electrical signal can be observed globally and locally by adjusting the amplitude range displayed on the monitoring interface. The calculated uterine contraction intensity can also be recorded on the uterine contraction intensity tracing curve. The degree of uterine activity during uterine contractions and the magnitude of uterine contraction pressure can be intuitively reflected by the amplitude size of the uterine contraction intensity tracing curve. The calculated uterine contraction peak value can be marked on the monitoring interface to annotate and prompt the uterine contractions. At the same time, the calculated baseline horizontal line can be traced on the monitoring interface, and the starting point and ending point of the uterine contractions can be reflected by the intersection points with the uterine contraction curve. The calculated time-domain parameters, frequency-domain parameters, and non-linear parameters related to the myometrial electrical signal can also be recorded on the monitoring interface. In addition, information such as the drug type, drug flow rate, and drug remaining amount in the infusion pump can be displayed on the monitoring interface, enabling medical staff to more intuitively understand the state of the pregnant woman. For example, the monitoring interface can be as Figure 2 shown.

[0124] The method for controlling the drug flow provided in this embodiment preprocesses the uterine electromyogram signal after acquiring it, and determines the characteristic parameters and / or contraction parameters according to the preprocessed uterine electromyogram signal, which can more accurately and efficiently determine the characteristic parameters and / or contraction parameters. After determining the characteristic parameters and / or contraction parameters, the characteristic parameters are input into the trained machine learning model to obtain the indication information output by the machine learning model, and then the infusion pump is controlled to adjust the drug flow rate according to the target parameters (contraction parameters and / or indication information) and individual characteristic information, which can further improve the accuracy of the controlled drug dosage. During the adjustment process, the relevant parameters are displayed on the monitoring interface, which can facilitate the medical staff to intuitively understand the status of the pregnant woman.

[0125] In this embodiment, a device for controlling the drug flow rate is also provided. This device is used to implement the above-mentioned embodiments and preferred implementation manners, and those that have been described will not be repeated. As used hereinafter, the term "module" can be a combination of software and / or hardware that can achieve a predetermined function. Although the devices described in the following embodiments are preferably implemented in software, implementation in hardware, or a combination of software and hardware is also possible and contemplated.

[0126] This embodiment provides a device for controlling the drug flow rate, as Figure 5 shown, including:

[0127] An acquisition module 501, configured to acquire the uterine electromyogram signal of the monitored pregnant woman;

[0128] A processing module 502, configured to determine the characteristic parameters and / or contraction parameters according to the uterine electromyogram signal, wherein the characteristic parameters and the contraction parameters are both used to characterize the uterine activity degree of the monitored pregnant woman, the characteristic parameters at least include one or more of time domain parameters, frequency domain parameters and non-linear parameters, and the contraction parameters at least include one or more of contraction intensity, contraction times, contraction frequency, contraction duration and contraction interval duration;

[0129] A control module 503, configured to control the infusion pump to adjust the drug flow rate according to the characteristic parameters and / or contraction parameters.

[0130] In some optional implementation manners, the control module 503 includes:

[0131] An input unit, configured to input the characteristic parameters into the trained machine learning model;

[0132] A first control unit, configured to control the infusion pump to adjust the drug flow rate according to the contraction parameters and / or the indication information output by the machine learning model.

[0133] In some optional implementation manners, the device includes:

[0134] A first acquisition unit, configured to acquire the individual characteristic information of the pregnant woman under monitoring, where the individual characteristic information includes at least one of name, age, gestational week, clinical symptom, and drug type;

[0135] A first control unit, including:

[0136] A first control subunit, configured to control an infusion pump to adjust the flow rate of a drug according to the individual characteristic information and a target parameter, where the target parameter is an indication information and / or a uterine contraction parameter.

[0137] In some alternative embodiments, the first control subunit includes:

[0138] A first determination unit, configured to determine the status of the pregnant woman under monitoring according to the individual characteristic information, where the status is a fetal protection status or an induction of labor status;

[0139] A first adjustment unit, configured to, when the pregnant woman under monitoring is in the fetal protection status, control the infusion pump to adjust the flow rate of the drug according to a first control strategy, where the indication information includes the first control strategy;

[0140] A second adjustment unit, configured to, when the pregnant woman under monitoring is in the induction of labor status, control the infusion pump to adjust the flow rate of the drug according to a second control strategy, where the indication information includes the second control strategy.

[0141] In some alternative embodiments, the first adjustment unit includes:

[0142] A first adjustment subunit, configured to, when the pregnant woman under monitoring is in the fetal protection status, if the uterine activity degree of the pregnant woman under monitoring is greater than or equal to a first preset uterine activity degree, control the infusion pump to increase the flow rate of the drug according to the first control strategy, where the uterine activity degree is determined based on the target parameter;

[0143] A second adjustment subunit, configured to, when the pregnant woman under monitoring is in the fetal protection status, if the uterine activity degree of the pregnant woman under monitoring is less than the first preset uterine activity degree, control the infusion pump to keep the flow rate of the drug unchanged according to the first control strategy.

[0144] In some alternative embodiments, the second adjustment unit includes:

[0145] A third adjustment subunit, configured to, when the pregnant woman under monitoring is in the induction of labor status, if the uterine activity degree of the pregnant woman under monitoring is greater than or equal to a second preset uterine activity degree, control the infusion pump to reduce the flow rate of the drug according to the second control strategy, where the uterine activity degree is determined based on the target parameter;

[0146] A fourth adjustment subunit, configured to, when a monitored pregnant woman is in an oxytocin state, if the uterine activity degree of the monitored pregnant woman is less than a second preset uterine activity degree, control an infusion pump to increase the flow rate of the drug according to a second control strategy.

[0147] In some alternative embodiments, the device further includes:

[0148] A stop module, configured to, during the process of increasing the flow rate of the drug in the infusion pump, if the flow rate of the drug reaches the maximum flow rate, control the infusion pump to stop increasing the flow rate of the drug.

[0149] In some alternative embodiments, the processing module 502 includes:

[0150] A first processing unit, configured to preprocess the uterine electromyogram signal to obtain a processed uterine electromyogram signal, where the preprocessing includes at least one of filtering out interference signals and rectification processing;

[0151] A second processing unit, configured to determine characteristic parameters and / or contraction parameters according to the processed uterine electromyogram signal.

[0152] In some alternative embodiments, the control module 503 includes:

[0153] A second control unit, configured to display at least one of the uterine electromyogram signal, characteristic parameters, contraction parameters, the flow rate of the drug in the infusion pump, the type of the drug in the infusion pump, and the remaining amount of the drug in the infusion pump through a display.

[0154] The further function descriptions of the above-mentioned various modules and units are the same as those in the corresponding embodiments above, and will not be elaborated here.

[0155] The device for controlling the drug flow rate in this embodiment is presented in the form of functional units. Here, the unit refers to an Application Specific Integrated Circuit (ASIC), a processor and a memory that execute one or more software or fixed programs, and / or other devices that can provide the above functions.

[0156] An embodiment of the present invention further provides a system for controlling the drug flow rate, as Figure 6 shown. The system includes a uterine electromyogram signal acquisition device 601, a processor 602, and an infusion pump 603.

[0157] Among them, the uterine electromyogram signal acquisition device 601 can be connected to the processor 602 in a wired or wireless (such as Bluetooth or wireless network) manner, and the infusion pump 603 can also be connected to the processor 602 in a wired or wireless manner.

[0158] Specifically, the uterine electromyogram signal acquisition device 601 is used to acquire the uterine electromyogram signal of the pregnant woman under monitoring. The uterine electromyogram signal acquisition device 601 can be the surface electrode patch and the lead wire in the above embodiments. The processor 602 is configured to obtain the uterine electromyogram signal from the uterine electromyogram signal acquisition device 601, to determine the characteristic parameters and / or the contraction parameters according to the uterine electromyogram signal, and to control the infusion pump to adjust the flow rate of the drug according to the characteristic parameters and / or the contraction parameters. Among them, both the characteristic parameters and the contraction parameters are used to characterize the activity degree of the uterus of the pregnant woman under monitoring. The characteristic parameters include at least one or more of the time domain parameters, the frequency domain parameters, and the non-linear parameters. The contraction parameters include at least one or more of the contraction intensity, the contraction frequency, the contraction duration, and the contraction interval duration.

[0159] Exemplarily, after obtaining the characteristic parameters and / or the contraction parameters according to the uterine electromyogram signal, the processor 602 can determine the activity degree of the uterus, and then determine the control strategy. Then, it can send an instruction to increase the drug flow rate, an instruction to decrease the drug flow rate, or an instruction to keep the flow rate unchanged to the infusion pump 603, and change the rotation speed of the infusion pump 603 through the instruction, so as to control the flow rate of the drug in the infusion pump 603.

[0160] Exemplarily, the processor in this embodiment is the device for controlling the drug flow rate in the above Figure 5 shown embodiment.

[0161] Further, in some optional embodiments, the system further includes a display 604. Specifically, the processor 602 is further configured to display at least one of the uterine electromyogram signal, the characteristic parameters, the contraction parameters, the flow rate of the drug in the infusion pump, the type of the drug in the infusion pump, and the remaining amount of the drug in the infusion pump through the display 604.

[0162] The embodiment of the present invention further provides a monitoring device having the device for controlling the drug flow rate as described above Figure 5 shown.

[0163] Please refer to Figure 7 , Figure 7 which is a schematic structural diagram of a monitoring device provided by an optional embodiment of the present invention. As shown in Figure 7As shown, the monitoring device includes: one or more processors 602, a memory 720, and interfaces for connecting various components, including a high-speed interface and a low-speed interface. Each component communicates with each other using different buses and can be installed on a common motherboard or in other ways as needed. The processor can process instructions executed within the monitoring device, including instructions stored in the memory or on the memory to display graphical information of the GUI on an external input / output device (such as a display device coupled to the interface). In some alternative embodiments, if necessary, multiple processors and / or multiple buses can be used together with multiple memories. Similarly, multiple monitoring devices can be connected, and each device provides some necessary operations (such as an array of servers, a set of blade servers, or a multi-processor system). Figure 7 In the figure, a processor 602 is taken as an example.

[0164] The processor 602 can be a central processing unit, a network processor, or a combination thereof. Among them, the processor 602 can further include a hardware chip. The above hardware chip can be an application-specific integrated circuit, a programmable logic device, or a combination thereof. The above programmable logic device can be a complex programmable logic device, a field programmable gate array, a generic array logic, or any combination thereof.

[0165] Among them, the memory 720 stores instructions executable by at least one processor 602, so that at least one processor 602 executes the method shown in the above embodiments.

[0166] The memory 720 can include a program storage area and a data storage area. Among them, the program storage area can store an operating system and application programs required for at least one function; the data storage area can store data created according to the use of the monitoring device, etc. In addition, the memory 720 can include a high-speed random access memory and can also include a non-transitory memory, such as at least one disk storage device, a flash memory device, or other non-transitory solid-state storage devices. In some alternative embodiments, the memory 720 can optionally include a memory remotely set relative to the processor 602, and these remote memories can be connected to the monitoring device through a network. Examples of the above network include but are not limited to the Internet, an enterprise intranet, a local area network, a mobile communication network, and combinations thereof.

[0167] The memory 720 can include a volatile memory, such as a random access memory; the memory can also include a non-volatile memory, such as a flash memory, a hard disk, or a solid-state drive; the memory 720 can also include a combination of the above types of memories.

[0168] The monitoring device further includes an input device 730 and an output device 740. The processor 602, the memory 720, the input device 730, and the output device 740 may be connected by a bus or other means. Figure 7 Taking the connection through the bus as an example.

[0169] The input device 730 can receive input digital or character information and generate key signal inputs related to the settings of pregnant women and function control of the monitoring device, such as a touch screen, a keypad, a mouse, a trackpad, a touchpad, a pointing stick, one or more mouse buttons, a trackball, a joystick, etc. The output device 740 may include a display device, an auxiliary lighting device (e.g., an LED), and a tactile feedback device (e.g., a vibration motor), etc. The above display device includes, but is not limited to, a liquid crystal display, a light-emitting diode, a display, and a plasma display. In some alternative embodiments, the display device may be a touch screen.

[0170] The embodiment of the present invention also provides a computer-readable storage medium. The method according to the embodiment of the present invention can be implemented in hardware, firmware, or be implemented as computer code that can be recorded on a storage medium, or be implemented by downloading through a network and originally stored in a remote storage medium or a non-transitory machine-readable storage medium and will be stored in a local storage medium, so that the method described herein can be stored in such software processing on a storage medium using a general computer, a dedicated processor, or programmable or dedicated hardware. Among them, the storage medium can be a magnetic disk, an optical disc, a read-only memory, a random access memory, a flash memory, a hard disk, or a solid-state drive, etc.; further, the storage medium may further include a combination of the above types of memories. It can be understood that a computer, a processor, a microprocessor controller, or programmable hardware includes a storage component that can store or receive software or computer code, and when the software or computer code is accessed and executed by the computer, the processor, or the hardware, the method shown in the above embodiment is implemented.

[0171] Although the embodiments of the present invention have been described in conjunction with the accompanying drawings, those skilled in the art can make various modifications and variations without departing from the spirit and scope of the present invention, and such modifications and variations all fall within the scope defined by the appended claims.

Claims

1. A method for controlling the drug flow rate, characterized in that The method includes: Obtaining the myoelectrical signal of the uterus of the pregnant woman under monitoring; Determining characteristic parameters and / or contraction parameters according to the myoelectrical signal of the uterus, wherein the characteristic parameters and the contraction parameters are both used to characterize the activity degree of the uterus of the pregnant woman under monitoring, the characteristic parameters at least include one or more of time domain parameters, frequency domain parameters and non-linear parameters, and the contraction parameters at least include one or more of contraction intensity, contraction frequency, contraction duration and contraction interval duration; Controlling an infusion pump to adjust the flow rate of the drug according to the characteristic parameters and / or the contraction parameters.

2. The method according to claim 1, characterized in that, The controlling the infusion pump to adjust the flow rate of the drug according to the characteristic parameters and / or the contraction parameters includes: Inputting the characteristic parameters into a trained machine learning model; Controlling the infusion pump to adjust the flow rate of the drug according to the contraction parameters and / or the indication information output by the machine learning model.

3. The method according to claim 2, wherein The method further includes: Obtaining the individual characteristic information of the pregnant woman under monitoring, wherein the individual characteristic information includes at least one of name, age, gestational week, clinical symptom and drug type; The controlling the infusion pump to adjust the flow rate of the drug according to the contraction parameters and / or the indication information output by the machine learning model includes: Controlling the infusion pump to adjust the flow rate of the drug according to the individual characteristic information and the target parameters, wherein the target parameters are the indication information output by the machine learning model and / or the contraction parameters.

4. The method according to claim 3, characterized in that, The controlling the infusion pump to adjust the flow rate of the drug according to the individual characteristic information and the target parameters includes: Determining the state of the pregnant woman under monitoring according to the individual characteristic information, wherein the state is a fetal protection state or an induction of labor state; When the pregnant woman under monitoring is in the fetal protection state, controlling the infusion pump to adjust the flow rate of the drug according to a first control strategy, wherein the indication information includes the first control strategy; When the pregnant woman under monitoring is in the induction of labor state, controlling the infusion pump to adjust the flow rate of the drug according to a second control strategy, wherein the indication information includes the second control strategy.

5. The method according to claim 4, characterized in that The controlling the infusion pump to adjust the flow rate of the drug when the pregnant woman under monitoring is in the fetal protection state includes: When the pregnant woman under monitoring is in the fetal protection state, if the activity degree of the uterus of the pregnant woman under monitoring is greater than or equal to a first preset activity degree of the uterus, then controlling the infusion pump to increase the flow rate of the drug according to the first control strategy, wherein the activity degree of the uterus is determined based on the target parameters; When the pregnant woman under monitoring is in the fetal protection state, if the activity degree of the uterus of the pregnant woman under monitoring is less than the first preset activity degree of the uterus, then controlling the infusion pump to keep the flow rate of the drug unchanged according to the first control strategy.

6. The method according to claim 4, wherein The controlling the infusion pump to adjust the flow rate of the drug when the pregnant woman under monitoring is in the induction of labor state includes: When the monitored pregnant woman is in the induced labor state, if the uterine activity degree of the monitored pregnant woman is greater than or equal to the second preset uterine activity degree, then according to the second control strategy, control the infusion pump to reduce the flow rate of the drug, wherein the uterine activity degree is determined based on the target parameter; When the monitored pregnant woman is in the induced labor state, if the uterine activity degree of the monitored pregnant woman is less than the second preset uterine activity degree, then according to the second control strategy, control the infusion pump to increase the flow rate of the drug.

7. The method according to claim 5 or 6, characterized in that The method further includes: During the process of increasing the flow rate of the drug in the infusion pump, if the flow rate of the drug reaches the maximum flow rate, then control the infusion pump to stop increasing the flow rate of the drug.

8. The method according to any one of claims 1 to 6, characterized in that, The determining the characteristic parameter and / or the uterine contraction parameter according to the myometrial electrical signal includes: Preprocess the myometrial electrical signal to obtain the processed myometrial electrical signal, wherein the preprocessing includes at least one of filtering out interference signals and rectification processing; Determine the characteristic parameter and / or the uterine contraction parameter according to the processed myometrial electrical signal.

9. The method according to any one of claims 1 to 6, characterized in that, The method further includes: Display at least one of the myometrial electrical signal, the characteristic parameter, the uterine contraction parameter, the flow rate of the drug in the infusion pump, the type of the drug in the infusion pump, and the remaining amount of the drug in the infusion pump through a display.

10. A device for controlling the flow rate of a drug, characterized in that, including: An acquisition module, configured to acquire the myometrial electrical signal of the monitored pregnant woman; A processing module, configured to determine a characteristic parameter and / or a uterine contraction parameter according to the myometrial electrical signal, wherein the characteristic parameter and the uterine contraction parameter are both used to characterize the uterine activity degree of the monitored pregnant woman, the characteristic parameter at least includes one or more of a time domain parameter, a frequency domain parameter, and a non-linear parameter, and the uterine contraction parameter at least includes one or more of uterine contraction intensity, uterine contraction times, uterine contraction frequency, uterine contraction duration, and uterine contraction interval duration; A control module, configured to control the infusion pump to adjust the flow rate of the drug according to the characteristic parameter and / or the uterine contraction parameter.

11. A system for controlling the drug flow rate, characterized in that, including a myometrial electrical signal acquisition device, a processor, and an infusion pump; The myometrial electrical signal acquisition device is configured to acquire the myometrial electrical signal of the monitored pregnant woman; The processor is configured to obtain the myometrial electrical signal from the myometrial electrical signal acquisition device, to determine a characteristic parameter and / or a uterine contraction parameter according to the myometrial electrical signal, and to control the infusion pump to adjust the flow rate of the drug according to the characteristic parameter and / or the uterine contraction parameter, wherein the characteristic parameter and the uterine contraction parameter are both used to characterize the uterine activity degree of the monitored pregnant woman, the characteristic parameter at least includes one or more of a time domain parameter, a frequency domain parameter, and a non-linear parameter, and the uterine contraction parameter at least includes one or more of uterine contraction intensity, uterine contraction times, uterine contraction frequency, uterine contraction duration, and uterine contraction interval duration.

12. The system according to claim 11, wherein The system further includes a display; The processor is further configured to display, via a display, at least one of the myometrial electrical signals, the characteristic parameters, the uterine contraction parameters, the flow rate of the drug in the infusion pump, the type of the drug in the infusion pump, and the remaining amount of the drug in the infusion pump.

13. A monitoring device, characterized in that, Comprising: A memory and a processor, the memory and the processor are communicatively connected to each other, the memory stores computer instructions, and the processor executes the computer instructions to execute the method according to any one of claims 1 to 9.

14. A computer-readable storage medium, characterized in that, Computer instructions are stored on the computer-readable storage medium, and the computer instructions are used to cause a computer to execute the method according to any one of claims 1 to 9.

Images